Table 6.
Characteristics of patients who developed AKI during follow-up (n = 4944)
| Metformin exposed AKI event | AKI event without concurrent metformin exposure | |
|---|---|---|
| (n = 1972) | (n = 2972) | |
| Age (Years) a | 73.6 (65.7 – 79.4) | 77.6 (70.4-83.7) |
| Male Sex (%) | 1161 (58.9) | 1533 (51.6) |
| HbA1c % | 7.2 (6.5- 8.3) | 6.8 (6.2- 7.9) |
| (mmol/mol) a | 55 (48- 67) | 51 (44- 63) |
| Diabetes Duration (years) a | 9.15 (5.11- 13.85) | 7.50 (3.30-13.76) |
| Number of diabetes drug classes (%) | ||
| 0 | 13 (0.7) | 1745 (58.7) |
| 1 | 830 (42.1) | 1049 (35.3) |
| 2 | 897 (45.5) | 162 (5.5) |
| 3 | 212 (10.8) | 16 (0.5) |
| 4 | 19 (1.0) | 0 (0.0) |
| 5 | 1 (0.1) | 0 (0.0) |
| CKD category (%) | ||
| >60 | 941 (47.7) | 986 (33.2) |
| 30-59 | 896 (45.4) | 1476 (49.37) |
| <29 ml/min/1.732 | 130 (6.6) | 492 (16.6) |
aMedian & IQR